Barrett’s Esophagus and Esophageal Adenocarcinoma Are Common After Treatment for Achalasia
- 404 Downloads
Achalasia is characterized by esophageal aperistalsis and impaired relaxation of the lower esophageal sphincter (LES). This contrasts with an insufficient LES, predisposing to gastro-esophageal reflux and Barrett’s esophagus. The co-incidence of achalasia and BE is rare. Pneumatic dilatation (PD) may lead to gastro-esophageal reflux, Barrett’s esophagus development, and esophageal adenocarcinoma.
To determine the incidence of Barrett’s esophagus and esophageal adenocarcinoma in achalasia patients treated with PD.
We performed a single-center cohort follow-up study of 331 achalasia patients treated with PD. Mean follow-up was 8.9 years, consisting of regular esophageal manometry, timed barium esophagram, and endoscopy.
Twenty-eight (8.4 %) patients were diagnosed with Barrett’s esophagus, one at baseline endoscopy. This corresponds with an annual incidence of Barrett’s esophagus of 1.00 % (95 % CI 0.62–1.37). Hiatal herniation was present in 74 patients and 21 developed Barrett’s esophagus compared to seven of 257 patients without a hiatal hernia. Statistical analysis revealed a hazard ratio of 8.04 to develop Barrett’s esophagus if a hiatal hernia was present. Post-treatment LES pressures were lower in patients with Barrett’s esophagus than in those without (13.9 vs. 17.4 mmHg; p = 0.03). Two (0.6 %) patients developed esophageal adenocarcinoma during follow-up.
Barrett’s esophagus is incidentally diagnosed in untreated achalasia patients despite high LES pressures, but is more common after successful treatment, especially in the presence of hiatal herniation. Patients treated for achalasia should be considered for GERD treatment and surveillance of development of Barrett’s esophagus, in particular, when they have low LES pressures and a hiatal herniation.
KeywordsAchalasia Barrett’s esophagus Esophageal adenocarcinoma Hiatus hernia Surveillance
Conflict of interest
- 1.Mayberry JF. Epidemiology and demographics of achalasia. Gastrointest Endosc Clin North Am. 2001;11:235–248, v.Google Scholar
- 6.de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030–1036.Google Scholar
- 9.Walzer N, Hirano I. Achalasia. Gastroenterol Clin North Am. 2008;37:807–825, viii.Google Scholar
- 10.Alderliesten J, Conchillo JM, Leeuwenburgh I, Steyerberg EW, Kuipers EJ. Predictors for outcome of failure of balloon dilatation in patients with achalasia. Gut. 2011;60:10–16.Google Scholar
- 15.Csendes A, Braghetto I, Burdiles P, Korn O, Csendes P, Henriquez A. Very late results of esophagomyotomy for patients with achalasia: clinical, endoscopic, histologic, manometric, and acid reflux studies in 67 patients for a mean follow-up of 190 months. Ann Surg. 2006;243:196–203.PubMedCrossRefGoogle Scholar
- 17.Sikkema M, de Jonge PJ, Steyerberg EW, Kuipers EJ. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2010;8:235–244; quiz e232.Google Scholar
- 26.Kuipers EJ. Barrett’s oesophagus, proton pump inhibitors and gastrin: the fog is clearing. Gut. 2010;59:148–149.Google Scholar
- 31.Orlando RC. Overview of the mechanisms of gastroesophageal reflux. Am J Med. 2001;111:174S–177S.Google Scholar
- 39.Hyun JJ, Bak YT. Clinical significance of hiatal hernia. Gut Liver. 2011;5:267–277.Google Scholar